TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrolimus Inhalation Powder

~ Inhaled Tacrolimus Powder Achieves Systemic Therapeutic Drug Levels ~ Anticipate Additional Safety Data in 3Q 2021 ~ Initiation of Lung Transplant Study Expected in 2H 2021

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

4 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here